Top News
Home >> Tag Archives: Qiagen—

Tag Archives: Qiagen—

QIAseq NGS panels, PCR kit

August 2018—Qiagen launched the QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit with a new generation of reagents to enable accurate microbial community profiling from complex microbiome samples. The UCP Multiplex PCR Kit is a standalone product as well as a component of the QIAseq 16S/ITS Panels.

Read More »

Qiagen broadens GeneReader applications

July 27, 2018—Qiagen has introduced next-generation sequencing solutions for a range of hereditary diseases on its GeneReader NGS System. The customizable QIAact target enrichment panels enable the analysis of more than 13 hereditary disease groups, including inherited cancers, cystic fibrosis, inherited cardiovascular diseases, and universal carrier screening. The solutions integrate the company’s QCI analysis, which includes the Human Gene Mutation ...

Read More »

Qiagen launches QIAstat-Dx in Europe

July 2018—Qiagen announced the European launch of its QIAstat-Dx, a next-generation multiplex molecular diagnostic that provides a one-step, fully integrated molecular analysis of common syndromes as tested for in syndromes in infections, oncology, and other diseases.

Read More »

Qiagen offers AdnaTest for lung, prostate cancers

April 20, 2018—Qiagen launched two liquid biopsy panels to evaluate circulating tumor cells in prostate and lung cancers. The AdnaTest ProstateCancerPanel AR-V7 Kit and AdnaTest LungCancer Kit were introduced at the American Association for Cancer Research annual meeting, April 14–18, in Chicago. The AdnaTest ProstateCancerPanel AR-V7 Kit detects the androgen receptor splice variant 7 in CTCs of prostate tumor origin ...

Read More »

IGRAs for immigration TB screening, 4/18

April 2018—The U.S. Centers for Disease Control and Prevention issued a notification to U.S. civil surgeons stating it will require the use of FDA-approved interferon gamma release assays for tuberculosis screening. The CDC plans for the changes to medical screening guidelines to go into effect Oct. 1.

Read More »

CDC to use IGRAs for immigration TB screening

Feb. 28, 2018—The U.S. Centers for Disease Control and Prevention issued a notification to U.S. civil surgeons stating it will require the use of FDA-approved interferon gamma release assays for tuberculosis screening. The CDC plans for the change to go into effect Oct. 1. The use of the tuberculin skin test will no longer be allowed for use in immigration screening, ...

Read More »

Qiagen to buy Stat-Dx

Feb. 20, 2018—Qiagen has entered into an agreement to acquire Stat-Dx, a developer of molecular diagnostics systems, for $147 million. Once the transaction is completed, which is expected later this year, Qiagen will launch the QIAstat-Dx system, a next-generation, fully integrated multiplex platform for syndromic disease testing. QIAstat-Dx enables scalable sample-to-insight processing of up to 48 molecular targets simultaneously and ...

Read More »

Qiagen, DiaSorin partnership, 2/18

February 2018—Qiagen and DiaSorin announced a partnership in which Qiagen’s QuantiFeron-TB diagnostic test will be added to the menu of DiaSorin’s Liaison family of analyzers, enabling customers of both companies to process QuantiFeron-TB Gold Plus, a fourth-generation assay for latent tuberculosis detection, on Liaison platforms. QFT-Plus is the first assay from the QuantiFeron portfolio that is planned to be adapted for use on the Liaison systems, with additional assays under consideration.

Read More »

Qiagen, Centogene join forces on rare disease testing, 1/18

January 2018—Qiagen and Centogene announced a collaboration and comarketing agreement to provide customers more complete sample-to-insight research and clinical testing solutions in rare genetic diseases. The collaboration includes the integration of Centogene’s CentoMD rare disease variant database into Qiagen’s bioinformatics offering to enhance test interpretation.

Read More »
X